比亞迪(01211.HK)簽署大灣區科技創新產業投資基金合夥協議 擬出資1億人幣
比亞迪(01211.HK)(002594.SZ)公佈,於今日(22日)簽署合夥協議,作爲有限合夥人之一,參與發起設立粵港澳大灣區科技創新產業投資基金(有限合夥),擬認繳出資1億元人民幣。
該基金專注於粵港澳大灣區科技創新關鍵領域的戰略投資基金,旨在以市場化、專業化方式加強科創企業投資,助力粵港澳大灣區國際科技創新中心建設,服務於建設粵港澳大灣區的國家戰略。該基金目前正在募集階段,目標總規模預計爲200億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.